Abbott India Limited (ABBOTINDIA.BO)
| Previous Close | 26,991.55 |
| Open | 27,163.30 |
| Bid | 27,484.15 x 0 |
| Ask | 27,532.70 x 0 |
| Day's Range | 27,076.55 - 27,600.00 |
| 52 Week Range | 21,661.75 - 29,628.15 |
| Volume | |
| Avg. Volume | 476 |
| Market Cap | 584.475B |
| Beta (5Y Monthly) | 0.07 |
| PE Ratio (TTM) | 48.54 |
| EPS (TTM) | 566.62 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | 410.00 (1.49%) |
| Ex-Dividend Date | Jul 18, 2024 |
| 1y Target Est | 7,799.25 |
- Reuters
Drugmaker Abbott India posts Q4 profit rise on higher sales
Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines. Revenues of drugmakers such as Abbott India and GlaxoSmithKline Pharma India, which get most of their business from India, have been impacted after the inclusion of some of their drugs in the government's essential medicines list in September 2022, making them susceptible to price caps. Abbott, which is a unit of U.S. healthcare firm Abbott Laboratories, has been trying to mitigate the impact of pricing curbs by driving up sales and cutting back on expenses.
- Reuters
Drugmaker Abbott India's Q3 profit rises on strong demand
Pharmaceutical firm Abbott India reported a 26% rise in third-quarter profit on Thursday, as higher sales outpaced the impact of a pricing cap on certain medicines. The company, which makes popular antacid medicine Digene, said its profit rose to 3.11 billion rupees ($37.5 million) from 2.47 billion rupees a year earlier. Revenues of drugmakers such as Abbott India, which get most of their business from India, continued to be affected during the quarter as some of their key drugs were included in the government's essential medicines list in September 2022, making them susceptible to price caps.
- Reuters
Abbott India warns of laxatives shortage in tussle with Goa regulator
Abbott Laboratories' Indian unit has warned of potential supply shortages of two popular laxative syrups after production was prohibited in India's Goa state, where drug inspectors have found lapses at a company factory, a letter shows. Goa, where Abbott has one of its two India plants, asked the company to halt production of Cremaffin and Duphalac syrups last month. The request followed the recall of another Abbott drug which triggered factory inspections by health officials who found contamination risks and sanitisation issues.
